摘要
靶向药物和免疫检查点抑制剂等系统治疗显著提高了晚期不可切除肝细胞癌病人的预后,但仍难以达到长期生存。转化治疗作为系统治疗与外科治疗结合的主要方向之一,使部分不可切除的肝细胞癌病人获得根治性切除与治愈的机会,近年在国内不同中心广泛开展,并在2021年发布首个《肝癌转化治疗中国专家共识》。同时应看到,在肝癌转化治疗的理论与实践中,还存在诸多关键性问题,目前尚无充足的循证证据回答。积极思考、探索并最终回答这些问题,对于建立、推广肝癌转化治疗的标准化理论体系至关重要。
Progress in the systemic therapies,represented by the molecular target therapies and immune checkpoint inhibitors(ICIs),have significantly improved the prognosis of unresectable hepatocellular carcinoma(uHCC),but long term survial remains limitted.As one of the major combination of systemic and surgical therapies,conversion therapy provides potentially curative opportunity to some uHCC patients.It is widely reported from different domestic centers.The first Chinese expert consensus about it was released in 2021.Yet at the same time,there are many key issues in the practice and theory remains to be resolved.Actively thinking,exploring and finally resolving these issues are essential for establishing and promoting the standardized theoretical system of uHCC conversion therapy.
作者
赵磊
钟敬涛
孙惠川
ZHAO Lei;ZHONG Jingtao;SUN Huichuan(Department of Hepatobiliary Pancreatic Surgery,Shandong Cancer Hospital and Institute,Shandong First Medical Univer-sity and Shandong Academy of Medical Science,Shandong Jinan 250117,China;Department of Liver Surgery and Trans-plantation,Liver Cancer Institute,Zhongshan Hospital,Fudan University,Shanghai 200032,China;不详)
出处
《外科理论与实践》
2024年第2期106-113,共8页
Journal of Surgery Concepts & Practice
基金
山东省重点与研发计划重特大疾病“防诊控治康”科技示范工程(2021SFGC0501)。
关键词
肝细胞癌
转化治疗
靶向治疗
免疫检查点抑制剂
系统性治疗
手术切除
Hepatocellular carcinoma
Conversion therapy
Target therapy
Immune checkpoint inhibitor(ICI)
Systemic therapy
Surgical resection
